AUTO-2 |
AUTO-2; SUB-96123 |
Phase 2 Clinical |
Autolus |
Multiple Myeloma |
Details
|
LCAR-B4822M |
LCAR-B4822M |
Phase 1 Clinical |
Genscript Biotech Corp |
Multiple Myeloma |
Details
|
bb-21217 |
bb-21217 |
Phase 1 Clinical |
Bluebird Bio |
Multiple Myeloma |
Details
|
SEA-BCMA |
SEA-BCMA; SGN-BCMA |
Phase 1 Clinical |
Seattle Genetics |
Multiple Myeloma |
Details
|
REGN-5459 |
REGN-5459 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Multiple Myeloma |
Details
|
HPN-217 |
HPN-217 |
Phase 2 Clinical |
Harpoon Therapeutics |
Multiple Myeloma |
Details
|
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) |
|
Phase 1 Clinical |
Wuhan Union Hospital, Shengyan Pharmaceutical Technology |
Multiple Myeloma |
Details
|
BCBM CAR T cell (Pregene) |
|
Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T-cell therapy (Arcellx) |
CART-ddBCMA |
Phase 1 Clinical |
Arcellx |
Multiple Myeloma |
Details
|
BCMA CAR-T Cells (Pregene) |
|
Phase 1 Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
AMG-420 |
AMG-420; BI-836909 |
Phase 1 Clinical |
Micromet |
Multiple Myeloma |
Details
|
PF-06863135 |
PF-06863135 |
Phase 2 Clinical |
Pfizer Pharmaceuticals Ltd (China) |
Multiple Myeloma |
Details
|
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) |
|
|
|
|
Details
|
CTX-120 |
CTX-120 |
Phase 1 Clinical |
Crispr Therapeutics |
Multiple Myeloma |
Details
|
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) |
|
Phase 1 Clinical |
|
Multiple Myeloma |
Details
|
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics |
Multiple Myeloma; Lymphoma |
Details
|
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Multiple Myeloma |
Details
|
TNB-383B |
TNB-383B |
Phase 1 Clinical |
Teneobio |
Multiple Myeloma |
Details
|
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase 1 Clinical |
|
Multiple Myeloma |
Details
|
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) |
BCMA-CART |
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Human BCMA chimeric antigen receptor autologous T cell(Nanjing Reindeer Medical Technology) |
CT103A |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd, Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase 1 Clinical |
The First Affiliated Hospital Of Nanchang University |
Multiple Myeloma |
Details
|
GC-012F |
GC-012F |
Phase 1 Clinical |
Genxi Biotechnology (Shanghai) Co Ltd |
Multiple Myeloma |
Details
|
P-BCMA-101 |
P-BCMA-101 |
Phase 2 Clinical |
Poseida Therapeutics |
Multiple Myeloma |
Details
|
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) |
|
Phase 1 Clinical |
Yake Biotechnology |
Multiple Myeloma |
Details
|
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) |
|
Phase 2 Clinical |
Asclepius Technology Company Group |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) |
|
Clinical |
Wuhan Bio-Raid Biotechnology |
Hematologic Neoplasms |
Details
|
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics |
Multiple Myeloma |
Details
|
BCMA CAR-T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Multiple Myeloma; Neoplasms, Plasma Cell |
Details
|
ACTR 087/SEA BCMA combination therapy |
|
Phase 1 Clinical |
Unum Therapeutics |
Multiple Myeloma |
Details
|
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase 3 Clinical |
First Affiliated Hospital,Suzhou University,Suzhou,China |
Multiple Myeloma |
Details
|
CC-98633 |
CC-98633 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
anti-BCMA CAR T-cell Therapy (Juno Therapeutics) |
FCARH-143; ET140-CAR; MCARH-171; JCARH-125; ET-140 |
Phase 2 Clinical |
Juno Therapeutics |
Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) |
CBG-002 CAR-T |
Phase 1 Clinical |
Yake Biotechnology Ltd |
Multiple Myeloma |
Details
|
HBI-0101 |
HBI-0101 |
|
Hadassah Medical Organization |
|
Details
|
CC-93269 |
EM-901; CC-93269 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
CC-99712 |
CC-99712 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
Teclistamab |
JNJ-64007957; JNJ-64007959; JNJ-7957 |
Phase 2 Clinical |
Janssen Global Services Llc, Genmab |
Hematologic Neoplasms; Multiple Myeloma |
Details
|
MEDI-2228 |
MEDI-2228 |
Phase 1 Clinical |
Medimmune Llc |
Multiple Myeloma |
Details
|
ALLO-715 |
ALLO-715 |
Phase 1 Clinical |
Cellectis, Allogene Therapeutics |
Multiple Myeloma |
Details
|
KITE-585 |
KITE-585 |
Phase 1 Clinical |
Kite Pharma, National Cancer Institute |
Multiple Myeloma |
Details
|
PBCAR-269A |
PBCAR-269A |
Phase 2 Clinical |
Precision Biosciences |
Multiple Myeloma |
Details
|
CAR-BCMA T cell therapy |
CT-053-CARsgen |
Phase 2 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Multiple Myeloma |
Details
|